Welcome. My name is Devine. This is episode 481 of the Devine Intervention

podcasts and into this podcast we're going to be going over inclusion bodies.

So let's call this the clutch inclusion body podcast. Now personally I tell people this. With these inclusion bodies a lot of the time the thing that makes the most

important sense to know is the clinical presentation. Most times on your

USMLI exams you're going to be getting these questions right by clinical

presentation.

So many of them honestly, trying to memorize how they look on histology in my experience is not a particularly

high-yield activity. Most times you get more bang for your buck by knowing how to identify these things, I mean from a clinical perspective.

But at the same time I am also going to talk about some unique features that you may see on on histology so I'll encourage you as you

listen to this podcast or after you listen to this podcast whip up some Google and do

some searching but again I kid you not most times is the clinical presentation that's going to be a helpful fact here.

Okay, so let's begin. So what did they give you a question about a 65 year old man and he tell you that for the past you know few months he has had a lot of

slowing of his movements and he tell you that we has a lot of tremors and whatnot.

Well, if you see something like this, I would really hope you're thinking about

Parkinson's disease.

Now, remember, Parkinson's disease, the primary place that's affected is the

substantial niger. So these people obviously have very low levels of

dopamine. So the substantial niger is affected, so they don't have adequate amounts of

dopamine. That's why if you notice it makes sense that many of the Parkinson's drugs

they stimulate dopamine receptors so things like bromo-crypton of carburegoline, or they increase the release of dopamine

in the central nervous system like a mandadine, or you're giving them straight up

dopamine like carbidopa, livo-dopa, right?

...